B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PRKAG1

MOLECULAR TARGET

protein kinase AMP-activated non-catalytic subunit gamma 1

UniProt: P54619NCBI Gene: 557110 compounds

PRKAG1 (protein kinase AMP-activated non-catalytic subunit gamma 1) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PRKAG1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Adenosine Monophosphate Adenine nucleotide containing2.208
2Proguanil1.956
3Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone1.614
4Niclosamide1.393
5Berberine1.102
6Ursolic Acid1.102
7Antimycin1.102
8Oleanolic Acid1.102
9Rotenone1.102
10Metformin0.691

About PRKAG1 as a Drug Target

PRKAG1 (protein kinase AMP-activated non-catalytic subunit gamma 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented PRKAG1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PRKAG1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.